We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Data Analysis and Management Solution
Product News

New Data Analysis and Management Solution

New Data Analysis and Management Solution
Product News

New Data Analysis and Management Solution


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New Data Analysis and Management Solution "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genedata has announced the release of Genedata Screener® Version 5.0, an enterprise solution for screen-to-lead research data analysis and management.
 
Screener 5.0 combines enterprise assay data management with high-performance processing workflows and flexible analysis tools. In addition, it provides access to a wide range of information from other reseach and drug discovery systems.

From low to ultra-high throughput screens, from single-point assays to complex high content screens – Screener rapidly analyzes, integrates, and manages all assay data, independent of instrumentation, technology, volume or location.

Screening data is combined with chemical, pharmacological and in vivo data to generate exactly the information scientists need to prioritize compounds and identify quality lead structures with the highest confidence.

Screener’s open and scalable architecture integrates with the existing corporate infrastructure as well as third party solutions and provides access to information from other corporate sources. Screener can be tailored to specific discovery processes, making it an integral as well as flexible element maximizing its value.
 
"Drug discovery processes are increasingly owned by interdisciplinary project teams. Compound screening using a portfolio of new technologies has become a strong support function for these teams, and screening data is regarded as an asset to be reused across the organization, for multiple projects.

This demands comprehensive data management, stringent quality control, and the integration of information,” explains Dr. Stephan Heyse, Business Head of Genedata Screener.

“Screener 5.0 enables drug researchers to focus on their primary objectives: to quickly evaluate entire campaigns, to compile and share relevant information for their specific projects, and to confidently identify high quality lead structures.

No other solution on the market provides such comprehensive data analysis and management features at such a high level of performance.”

Advertisement